J&J faces FTC probe on Remicade biosimilar defenceJohnson & Johnson’s antibody blockbuster Remicade has proved highly resistant to biosimilar competition – so much so that Share XJ&J faces FTC probe on Remicade biosimilar defencehttps://pharmaphorum.com/news/jj-faces-ftc-probe-on-remicade-biosimilar-defence/